Thursday, June 24, 2021
Home RDIF and Panacea Biotec start Sputnik V vaccine production in India

RDIF and Panacea Biotec start Sputnik V vaccine production in India

The Russian Direct Investment Fund (RDIF) and Panacea Biotec have started production of Sputnik V in India. Panacea Biotec will now be able to produce 100 million doses in the country every year. RDIF stated that the first batch of vaccines produced by Panacea Biotech will be sent to Sputnik V developer Gamaleya Centre in Russia, for quality control. Its full scale production is expected to begin in summer this year. Established in 1984, Panacea Biotech produces a wide range of drugs and vaccines. The Sputnik V vaccine, registered in 65 countries, uses two different adenovirus vectors in the first and second doses. According to leading medical magazine Lancet, Sputnik V is 91.6% effective against coronavirus infection.

Know more: ANI Twitter

Read more: Livemint | Money Control | The Indian Express

50% LikesVS
50% Dislikes

News Verification For Headline Auditors

If this seems like a news that is relevant to your industry. Would you like to verify the authenticity of the news?
Please Enter your Secret Key

We are building a board of industry expert to help us verify important news stories. If you would like to empanel yourself, please click here.

Report Post

Avantika Yadav
23, Content Editor @HeadlineEnglish @HeadlineHindi



Your opinion matters to us!

Get 500 Points For Review. Create Profile, Mention Profile Name In The Review Section. Get Points in 24 hours.

No, Thanks!


Note: Please create your profile so we can send the points to your account